NovaBay Pharmaceuticals To Present Data On Lead Anti-Infective Compound at First-Ever ICAAC/IDSA Joint Meeting

By October 7, 2008

NovaBay Pharmaceuticals, Inc. (AMEX: NBY & TSX: NBY, www.novabaypharma.com), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, will deliver four poster presentations and an oral summary during the first-ever joint meeting of the American Society for Microbiology and the Infectious Diseases Society of America (48th Annual ICAAC/IDSA 46th Annual Meeting) in Washington, D.C.

The four poster presentations, describing new results from the company’s antibacterial program, will be given on Tuesday, October 28, between 11:15 AM – 12: 15 PM. The first explains the chemistry and basic biology of NovaBay’s lead compound, NVC-422, a broad-spectrum antibacterial belonging to a class of naturally occurring antibacterial compounds. The second describes the biological activity of NVC-422 in greater detail. The third examines more closely the use of NVC-422 against biofilms – troublesome “communities” of microorganisms that adhere to a living or inert surface, for example a catheter or medical implant. The final poster describes research that indicates that NVC-422 is highly unlikely to engender resistance. By invitation, NovaBay will be providing an oral summary of these posters during the Poster Summary Session on Novel Antimicrobial Agents and Strategies on Saturday, October 25 between 10 AM and 12 noon.

“We are proud of the progress we have made in our research and clinical development of antimicrobial compounds and are delighted to have been asked to present an oral summary at this prestigious meeting,” said Dr. Ron Najafi, CEO of Novabay Pharmaceuticals. “We would like to acknowledge the contributions of NovaBay scientists whose innovative work is partly summarized in these posters. We continue to discover new characteristics of these Aganocide® compounds, enabling us to further expand the number of potential indications where they may help improve people’s health and ultimately save lives.”

About ICAAC/IDSA Joint Meeting
More than 12,000 physicians, researchers, and other health care professionals from around the globe will gather at this Joint Meeting to review the latest scientific and clinical findings on infectious diseases.

The Joint Program Committee has selected a faculty that includes internationally renowned scientists to broaden and enrich your experience. In addition to invited speakers, there will be both slide and poster abstract presentations.

About NovaBay
NovaBay Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of non-antibiotic anti-infective compounds, which it has named Aganocide® compounds, which are based upon small molecules that are generated by white blood cells to defend the body against invading pathogens. NovaBay believes that Aganocide® compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of not only bacterial and viral infections, but also Staphylococcus aureus (including resistant strains known as MRSA) without developing resistance, a serious problem that invariably plagues all antibiotics. NovaBay has entered into a licensing and research collaboration agreement with Alcon Laboratories, Inc. for use of the Aganocide® compounds in the eye, ear and sinus, and in contact lens solutions. The company also has a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NovaBay’s NeutroPhase product in wound care applications.

NovaBay™, Aganocide®, AgaNase™, and NeutroPhase™ are trademarks of NovaBay Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners.

Forward-Looking Statements
This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the market opportunities for, NovaBay’s product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Contact:

Investors:
NovaBay Pharmaceuticals Contacts
Theresa Granados
510-899-8870
Head of Investor Relations
tgranados@novabaypharma.com

or
The Investor Relations Group
Investor Relations:
Adam Holdsworth / Erica Ruderman / Brett Foley
212-825-3210
or
Media Relations:
Janet Vasquez / Laura Colontrelle
212-825-3210

TOP